GlassScriptPhysician profile
Keri Jo Smith
NPI 1720533201
$7,081.96
in general payments reported to CMS, 2019-2025
43 companies · $4,756 in 2025
The $4,756 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $11.71 · 2023: $13.93 · 2024: $2,301 · 2025: $4,756.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,070.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,070.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $827.76 | 2024-2025 | |
| Biogen, INC. | $711.18 | 2024-2025 | Vumerity, Tysabri, Skyclarys |
| Jazz Pharmaceuticals INC. | $684.96 | 2024-2025 | |
| Abbvie INC. | $437.99 | 2024-2025 | |
| Argenx US, INC. | $408.15 | 2025 | Vyvgart, Vyvgart Hytrulo |
| Amgen INC. | $355.61 | 2024-2025 | Uplizna |
| Lilly USA, LLC | $335.05 | 2022-2025 | Kisunla, Amyvid, Emgality |
| Ucb, INC. | $318.28 | 2024-2025 | Briviact, Nayzilam |
| Teva Pharmaceuticals USA, INC. | $308.59 | 2024-2025 | Austedo Xr, Austedo Xr |
| Avadel Cns Pharmaceuticals, LLC | $298.35 | 2024-2025 | Lumryz |
| Livanova USA, INC. | $276.09 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Neurocrine Biosciences, INC. | $253.33 | 2024-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $231.72 | 2024-2025 | Sunosi, Symbravo, Auvelity |
| Tg Therapeutics, INC. | $217.22 | 2024-2025 | |
| Acadia Pharmaceuticals INC | $211.57 | 2024-2025 | Nuplazid |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $186.10 | 2025 | |
| Alexion Pharmaceuticals, INC. | $131.14 | 2024 | Ultomiris |
| Ani Pharmaceuticals, INC. | $124.99 | 2025 | Purified Cortrophin Gel |
| Catalyst Pharmaceuticals, INC. | $76.28 | 2024-2025 | |
| Neurelis, INC. | $64.74 | 2025 | Valtoco |
| Sk Life Science, INC. | $54.80 | 2024-2025 | Xcopri |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $50.81 | 2025 | Rexulti |
| Scilex Pharmaceuticals INC. | $48.52 | 2024-2025 | |
| Harmony Biosciences LLC | $46.40 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $45.81 | 2025 | Caplyta |
| Acorda Therapeutics, INC | $38.18 | 2024 | Ampyra, Inbrija |
| Octapharma USA, INC. | $28.96 | 2025 | Panzyga |
| Impel Pharmaceuticals LLC | $27.30 | 2025 | Trudhesa |
| E.R. Squibb & Sons, L.L.C. | $25.77 | 2024 | Zeposia |
| Celgene Corporation | $25.29 | 2025 | Zeposia |
| Aucta Pharmaceuticals, INC. | $24.11 | 2025 | Motpoly Xr |
| Lundbeck LLC | $22.67 | 2024 | Rexulti |
| Springworks Therapeutics, INC. | $21.48 | 2025 | Gomekli |
| Tanabe Pharma America, INC. | $21.09 | 2025 | Radicava |
| Astellas Pharma US INC | $19.04 | 2024 | Veozah |
| Otsuka America Pharmaceutical, INC. | $18.86 | 2025 | Rexulti |
| Cycle Pharmaceuticals INC | $18.21 | 2025 | Bafiertam |
| Genentech USA, INC. | $14.76 | 2025 | Ocrevus Zunovo |
| Tris Pharma INC | $14.66 | 2024 | Dyanavel Xr |
| Cala Health, INC. | $14.53 | 2024 | Cala Kiq, Cala Trio |
| Merz Pharmaceuticals, LLC | $14.19 | 2025 | Ampyra, Inbrija, Xeomin |
| Novo Nordisk INC | $13.93 | 2023 | Ozempic, Rybelsus |
| Emd Serono, INC. | $13.49 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keri Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.